ERYP vs. PRME, IKT, PLX, IZTC, ACHL, CRTX, BLUE, ZIVO, CYTH, and FNCH
Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Achilles Therapeutics (ACHL), Cortexyme (CRTX), bluebird bio (BLUE), ZIVO Bioscience (ZIVO), Cyclo Therapeutics (CYTH), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
ERYTECH Pharma vs. Its Competitors
ERYTECH Pharma (NASDAQ:ERYP) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.
In the previous week, Prime Medicine had 9 more articles in the media than ERYTECH Pharma. MarketBeat recorded 9 mentions for Prime Medicine and 0 mentions for ERYTECH Pharma. Prime Medicine's average media sentiment score of 1.02 beat ERYTECH Pharma's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
1.1% of ERYTECH Pharma shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Comparatively, 22.9% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Prime Medicine has a consensus price target of $10.08, indicating a potential upside of 131.80%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than ERYTECH Pharma.
ERYTECH Pharma's return on equity of 0.00% beat Prime Medicine's return on equity.
ERYTECH Pharma has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.33, indicating that its share price is 133% more volatile than the S&P 500.
ERYTECH Pharma has higher revenue and earnings than Prime Medicine.
Summary
Prime Medicine beats ERYTECH Pharma on 9 of the 14 factors compared between the two stocks.
Get ERYTECH Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ERYTECH Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ERYP) was last updated on 7/12/2025 by MarketBeat.com Staff
Free ERYP Stock Alerts